Blair William & Co. IL grew its holdings in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 11.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 787,845 shares of the specialty pharmaceutical company’s stock after purchasing an additional 80,975 shares during the quarter. Blair William & Co. IL owned approximately 1.11% of BioDelivery Sciences International worth $2,206,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in BioDelivery Sciences International in the 3rd quarter valued at approximately $255,000. Fosun International Ltd acquired a new stake in shares of BioDelivery Sciences International during the third quarter worth $1,462,000. JPMorgan Chase & Co. boosted its holdings in BioDelivery Sciences International by 35.8% in the third quarter. JPMorgan Chase & Co. now owns 267,874 shares of the specialty pharmaceutical company’s stock valued at $750,000 after acquiring an additional 70,633 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in BioDelivery Sciences International by 121.7% in the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock valued at $331,000 after acquiring an additional 64,803 shares during the last quarter. Finally, Alpha Omega Wealth Management LLC acquired a new position in BioDelivery Sciences International in the third quarter valued at $3,668,000. 53.16% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Francis E. Odonnell, Jr. sold 151,039 shares of BioDelivery Sciences International stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $2.84, for a total transaction of $428,950.76. Following the sale, the director now directly owns 520,482 shares of the company’s stock, valued at $1,478,168.88. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $3.84, for a total value of $30,720.00. Following the sale, the director now directly owns 522,187 shares in the company, valued at $2,005,198.08. The disclosure for this sale can be found here. Insiders sold 175,039 shares of company stock worth $511,431 over the last three months. 13.26% of the stock is currently owned by corporate insiders.

A number of research analysts recently weighed in on BDSI shares. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Cantor Fitzgerald set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, October 26th. BidaskClub lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a research report on Friday, August 10th. Finally, Janney Montgomery Scott raised their price objective on BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a research report on Friday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. BioDelivery Sciences International presently has a consensus rating of “Buy” and an average price target of $4.54.

NASDAQ:BDSI opened at $3.79 on Thursday. The company has a debt-to-equity ratio of 1.42, a quick ratio of 2.77 and a current ratio of 3.00. BioDelivery Sciences International, Inc. has a 12 month low of $1.70 and a 12 month high of $4.14.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04. BioDelivery Sciences International had a negative return on equity of 141.35% and a negative net margin of 85.93%. The company had revenue of $14.16 million for the quarter, compared to analyst estimates of $14.21 million. Research analysts anticipate that BioDelivery Sciences International, Inc. will post -0.61 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/blair-william-co-il-grows-stake-in-biodelivery-sciences-international-inc-bdsi/2664014.html.

BioDelivery Sciences International Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: Trading Penny Stocks

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.